We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Incyte (INCY - Free Report) will report quarterly earnings of $1.94 per share in its upcoming release, pointing to a year-over-year increase of 35.7%. It is anticipated that revenues will amount to $1.35 billion, exhibiting an increase of 14.2% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Incyte metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Net product revenues- Minjuvi/ Monjuvi' to come in at $41.19 million. The estimate points to a change of +25.6% from the year-ago quarter.
Analysts forecast 'Net product revenues- Pemazyre' to reach $22.94 million. The estimate indicates a change of -0.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Product revenues' should come in at $1.17 billion. The estimate indicates a year-over-year change of +14.5%.
Analysts' assessment points toward 'Net product revenues- Jakafi' reaching $799.29 million. The estimate indicates a year-over-year change of +3.4%.
The collective assessment of analysts points to an estimated 'Net product revenues- Opzelura' of $196.54 million. The estimate indicates a year-over-year change of +21.6%.
The combined assessment of analysts suggests that 'Net product revenues- Iclusig' will likely reach $30.82 million. The estimate indicates a year-over-year change of +12.6%.
The consensus among analysts is that 'Revenues- Product royalty revenues' will reach $172.83 million. The estimate indicates a change of +8.5% from the prior-year quarter.
The consensus estimate for 'Royalty revenues- Tabrecta' stands at $8.60 million. The estimate points to a change of +36.7% from the year-ago quarter.
Analysts predict that the 'Royalty revenues- Olumiant' will reach $40.09 million. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Royalty revenues- Jakavi' should arrive at $124.64 million. The estimate suggests a change of +9.2% year over year.
Over the past month, Incyte shares have recorded returns of -7.2% versus the Zacks S&P 500 composite's +0.5% change. Based on its Zacks Rank #3 (Hold), INCY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Incyte (INCY - Free Report) will report quarterly earnings of $1.94 per share in its upcoming release, pointing to a year-over-year increase of 35.7%. It is anticipated that revenues will amount to $1.35 billion, exhibiting an increase of 14.2% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Incyte metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Net product revenues- Minjuvi/ Monjuvi' to come in at $41.19 million. The estimate points to a change of +25.6% from the year-ago quarter.
Analysts forecast 'Net product revenues- Pemazyre' to reach $22.94 million. The estimate indicates a change of -0.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Product revenues' should come in at $1.17 billion. The estimate indicates a year-over-year change of +14.5%.
Analysts' assessment points toward 'Net product revenues- Jakafi' reaching $799.29 million. The estimate indicates a year-over-year change of +3.4%.
The collective assessment of analysts points to an estimated 'Net product revenues- Opzelura' of $196.54 million. The estimate indicates a year-over-year change of +21.6%.
The combined assessment of analysts suggests that 'Net product revenues- Iclusig' will likely reach $30.82 million. The estimate indicates a year-over-year change of +12.6%.
The consensus among analysts is that 'Revenues- Product royalty revenues' will reach $172.83 million. The estimate indicates a change of +8.5% from the prior-year quarter.
The consensus estimate for 'Royalty revenues- Tabrecta' stands at $8.60 million. The estimate points to a change of +36.7% from the year-ago quarter.
Analysts predict that the 'Royalty revenues- Olumiant' will reach $40.09 million. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Royalty revenues- Jakavi' should arrive at $124.64 million. The estimate suggests a change of +9.2% year over year.
View all Key Company Metrics for Incyte here>>>Over the past month, Incyte shares have recorded returns of -7.2% versus the Zacks S&P 500 composite's +0.5% change. Based on its Zacks Rank #3 (Hold), INCY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .